Your browser version may not work well with NCBI's Web applications. More information here...
1: Am J Ophthalmol. 2007 Aug;144(2):296-9.Click here to read Links

Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.

Maia OO Jr, Bonanomi MT, Takahashi WY, Nascimento VP, Takahashi BS.

Retina and Vitreous Service, Department of Ophthalmology, University of São Paulo, São Paulo, Brazil. omaiausp@uol.com.br

PURPOSE: To report the use of intravitreal bevacizumab injection for the treatment of foveal detachment in idiopathic perifoveal telangiectasia (IPT). DESIGN: Prospective, interventional case series. METHODS: Three eyes from two patients with IPT and foveal detachments were treated with a 1.25 mg/0.05 ml intravitreal injection of bevacizumab. The following variables were evaluated: visual acuity and optical coherence tomography (OCT) images. RESULTS: The OCT images showed marked reversal of the foveal detachment after the injection, with restoration of foveal depression in all eyes. The vision of all treated eyes improved and remained unchanged up until the last follow-up visit (mean, 24 weeks). CONCLUSIONS: A single intravitreal bevacizumab injection provides short-term improvement in visual acuity and foveal detachment associated with IPT. These findings should be followed by further studies to evaluate the long-term effects on retinal structure and function.

PMID: 17659962 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Bevacizumab Injection (Avastin® )

    Bevacizumab is used with chemotherapy to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Bevacizumab is also used with chemotherapy to treat certain types of lung cancer....

  • Source: AHFS Consumer Medication Information